Abstracts 53 ically requested, were included in 18 dossiers, and offlabel information was included in 7. Of the 50 products submitted, 24 (48%) were added to Formulary. CON-CLUSIONS: Compliance with the guidelines has improved over the past 30 months. Overall, a majority of the submissions included complete clinical information and some type of economic analysis. There remains, however, significant opportunity for improvement, particularly in the presentation of economic evaluation data and the dissemination of unpublished studies.
Obesity is now recognized as a chronic health condition instead of a cosmetic or lifestyle issue. Orlistat and sibutramine are effective weight-loss/weight-maintenance agents. Insurers argue that the high prevalence of obesity (i.e., body mass index (BMI) 3 30kg/m 2 ), questionable long-term health benefits, and cost of these drugs make it unfeasible to cover them. Proponents claim decreases in obesity's comorbidities would offset acquisition costs. OBJECTIVES: To provide evidence for a rational reimbursement policy for pharmacological treatments of obesity in adults. METHODS: A Markov decision analytic model was used to evaluate the cost-effectiveness of orlistat (120mg TID) and sibutramine (5-20mg QD) relative to diet and exercise alone. The model analyzed a hypothetical population of obese, but otherwise healthy 30 year olds over their lifetime. Estimates of efficacy and tolerance were derived from a meta-analysis of randomized, placebo-controlled trials of orlistat and sibutramine. The Framingham Study was used to derive risk-adjusted equations for the incidence of hypertension, dyslipidemia, and DM as well as the incidence of CV events, CV-attributable death, and non-CV death. Equations were adjusted for known risk factors, including BMI. The reference case analysis used the societal perspective and included both direct and indirect costs (discount rate, 3%). Costs were derived from the literature and inflated to year 2000 Canadian dollars (CDN$). Utilities were derived from a Canadian health survey and from the literature. Decision index: incremental cost per quality adjusted life year ($/QALY). A Monte Carlo simulation will be used to perform a sensitivity analyses around: estimated weight-loss, estimated dropout rates, estimated weight regain, cost of treatment, and major clinical events. RESULTS: Results for the base case (i.e., societal viewpoint) and third party payer (i.e., Ministry of Health) perspectives will be presented and discussed. Emphasis will be placed on the decision model approach for informing formulary decisions on "lifestyle" drugs. Cost-utility analysis is rapidly becoming the standard pharmacoeconomic measure in oncology. In a recent report (JCO, 2000; 18:3302) , data from 40 published costutility studies were presented in a league table format. Most of those studies utilized nurses or physicians as proxies for the pt. in determining utility. OBJECTIVE:
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CN1
UTILITIES OF METASTATIC BREAST CANCER PATIENTS (PT) TREATED WITH TAXANES COMPARED TO UTILITIES OF ONCOLOGY NURSES (NUR)
To determine if there is a difference between utility scores obtained from metastatic breast cancer pt. and oncology nurses. METHODS: Using eight modified Markov modeled health states (Pharmacoeconomics, 1996; 60:504) describing metastatic breast cancer; the standard gamble procedure was utilized to obtain utility scores from 45 patients and 57 oncology nurses. Utility values were measured on a scale between 0.0 and 1.0. Independent t-tests were used to test for differences between groups using an alpha level of 0.05 (2-sided). RESULTS: Significant differences were found on all eight modeled health states: CONCLUSION: These results show that patients have a higher utility for health than perceived by nurses. These data leads to the question of whose utility values should be used for cost-utility analysis in oncology. 
CN2
EFFECT OF INCLUDING (VERSUS EXCLUDING) FATES WORSE THAN DEATH ON UTILITY MEASUREMENT
